LPU
CYTK icon

Lansdowne Partners (UK)’s Cytokinetics CYTK Stock Holding History

Lansdowne Partners (UK)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,459,706
Closed -$11.8M – 34
2019
Q1 		$11.8M Sell
1,459,706
-1,188,275
-45% -$8.74M 0.26% 27
2018
Q4 		$16.7M Hold
2,647,981
– – 0.25% 21
2018
Q3 		$26.1M Hold
2,647,981
– – 0.28% 21
2018
Q2 		$22M Hold
2,647,981
– – 0.21% 26
2018
Q1 		$19.1M Hold
2,647,981
– – 0.2% 19
2017
Q4 		$21.6M Hold
2,647,981
– – 0.2% 18
2017
Q3 		$38.4M Hold
2,647,981
– – 0.4% 14
2017
Q2 		$32M Buy
2,647,981
+326,116
+14% +$4.53M 0.28% 17
2017
Q1 		$29.8M Hold
2,321,865
– – 0.26% 16
2016
Q4 		$28.2M Hold
2,321,865
– – 0.25% 15
2016
Q3 		$21.3M Hold
2,321,865
– – 0.18% 15
2016
Q2 		$22M Hold
2,321,865
– – 0.21% 17
2016
Q1 		$16.4M Hold
2,321,865
– – 0.13% 18
2015
Q4 		$24.3M Hold
2,321,865
– – 0.17% 18
2015
Q3 		$15.5M Hold
2,321,865
– – 0.13% 17
2015
Q2 		$15.6M Hold
2,321,865
– – 0.13% 18
2015
Q1 		$15.7M Hold
2,321,865
– – 0.14% 19
2014
Q4 		$18.6M Hold
2,321,865
– – 0.17% 24
2014
Q3 		$8.17M Hold
2,321,865
– – 0.07% 31
2014
Q2 		$11.1M Buy
+2,321,865
New +$14.2M 0.11% 30

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Lansdowne Partners (UK)'s CYTK Position: Q2 2019 in Review

Lansdowne Partners (UK) sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 1,459,706 shares — an estimated $11.8M sold.

Lansdowne Partners (UK) first reported a position in CYTK in Q2 2014 and held it in 20 quarters. The position peaked at $38.4M in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

  • Lansdowne Partners (UK) reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
  • Lansdowne Partners (UK) sold 1,459,706 Cytokinetics shares in Q2 2019, an estimated $11.8M.
  • Lansdowne Partners (UK) first reported a position in Cytokinetics in Q2 2014 and held it in 20 quarters.
  • Lansdowne Partners (UK)'s Cytokinetics position peaked at $38.4M in Q3 2017.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on Lansdowne Partners (UK)'s 13F filing for Q2 2019, filed 13 Aug 2019.